FIGURE 9.
Control of d16 sphingolipid levels and SPTLC3 expression by fatty acids. A, treatment with the saturated fatty acid myristate (Myr; C14:0), but not palmitate (Pal; C16:0), stimulated production of d16:1-ceramide (Cer) and d16:0-dihydroceramide (DHC). B, myristate, but not palmitate, treatment also stimulated an increase in SPTLC3 mRNA levels. Primary adult cardiomyocytes were treated with BSA or fatty acid conjugated to BSA, as indicated, for 16 h. Lipids and RNA were extracted and prepared for analysis by LC-MS or qRT-PCR, respectively, as indicated under “Materials and Methods.” Results are presented as mean ± S.E. (error bars). *, p < 0.05 versus BSA; #, p < 0.05 versus palmitate.